BYND Beyond Meat slides 8 after Q4 2025 EPS misses estimates by a wide margin to sour investor sentiment J Jacobs Solutions edges down 077 after Q1 2026 EPS lands 1 below analyst consensus estimates Gilead Sciences GILD Valuation Implications of Expanded Kymera Therapeutics Collaboration and Kymeras FDA Fast Track Designation Is COPT Defense CDP stock moving sideways Q4 2025 EPS Misses Views CHTR Charter shares plunge 255 today after Q1 2026 EPS falls 111 short of analyst estimates